查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1454246

支氣管擴張劑的全球市場：按藥物類別、給藥途徑、適應症、分銷管道和地區分類。

Global Bronchodilators Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography .
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年，全球支氣管擴張劑市值為228.5億美元，預計2031年將達到304.4億美元，2024年至2031年的年複合成長率（CAGR）預計將成長3.6%。

報告範圍 報告詳情
基準年 2023年 2023/2024年市場規模 228.5億美元
實際資料 2019-2023 預測期 2024-2031
預測期2023/2024~2030/2031年複合成長率： 3.60% 2030/2031價值預測 304.4億美元
圖 1. 2023 年支氣管擴張劑的全球市場佔有率(%)（按地區）
全球支氣管擴張劑市場-IMG1

支氣管擴張劑是擴張肺部氣道以使呼吸更容易的藥物。支氣管擴張劑的作用是放鬆和擴張支氣管周圍的平滑肌，減少喘息、咳嗽、氣短以及與氣喘和慢性阻塞性肺病(COPD) 等呼吸系統疾病相關的其他症狀。支氣管擴張劑包括短效藥物和長效藥物，前者用於短期緩解突然發作的呼吸困難，後者用於控制氣喘和慢性阻塞性肺病的呼吸困難，並抵消皮質類固醇對氣喘的影響。提升的版本。抗膽鹼能藥物（也稱為抗毒蕈鹼藥）主要用於治療慢性阻塞性肺病，但有些也可用於治療氣喘。抗膽鹼能藥物透過阻斷膽鹼能神經來擴大氣道。支氣管擴張劑的副作用因特定藥物而異。支氣管擴張劑的常見副作用包括手部顫抖、頭痛、肌肉痙攣、噁心和嘔吐以及腹瀉等。

市場動態：

全球支氣管擴張劑市場的成長是由於老年人口的增加（更容易患呼吸道疾病）、都市區和農村地區環境污染水平的上升以及對氣喘和慢性阻塞性肺病（COPD）正確管理的認知等因素造成的。例如增加然而，替代治療方案的可用性、長期使用支氣管擴張劑相關的副作用、重磅藥物的專利到期等是預期抑制市場成長的一些主要因素。聯合治療的開拓，即可以同時施用兩種或多種藥物，正在為該市場的參與者創造新的機會。此外，越來越重視預防性吸入療法以更好地管理呼吸道症狀可能會推動未來的需求。

本研究的主要特點

  • 該報告詳細分析了全球支氣管擴張劑市場，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%）。
  • 它還說明了各個細分市場的潛在商機，並為該市場提供了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
  • 主要公司簡介包括 GSK plc.、AstraZeneca、Mylan NV、Merck &Co, Inc.、Sun Pharmaceutical Industries Ltd.、Glenmark Pharmaceuticals Limited、Novartis AG、Boehringer Ingelheim International GmbH、Teva Pharmaceutical Industries Ltd.、Cipla Inc.、Sunovion Ingelheim International GmbH、Teva Pharmaceutical Industries Ltd.、Cipla Inc.、Sunovion Ingelticals Inc. .、賽諾菲和Innoviva。
  • 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 全球支氣管擴張劑市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球支氣管擴張劑市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 研究目的與前提

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map（COM）

第3章市場動態、法規及趨勢分析

  • 市場動態
    • 增加產品核准
    • 嚴格的法規環境
    • 加強宣傳宣傳活動
  • 主要亮點
  • 監管場景
  • 市場趨勢
  • 管道分析
  • 產品發布/核准
  • PEST分析
  • 波特的分析
  • 流行病學
  • 治療流程（病人歷程）
  • 治療方案分析
  • 主要市場參與者的新投資
  • 價格分析
  • 疾病意識計劃
  • 治療安全性和有效性分析
  • 合併、收購和合作

第4章全球支氣管擴張劑市場－冠狀病毒（COVID-19）大流行的影響

  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 供需面分析
  • 經濟影響

第5章全球支氣管擴張劑市場，依藥物類別，2019-2031

  • BETA-腎上腺素能支氣管擴張劑
  • 黃嘌呤衍生物
  • 抗膽鹼能支氣管擴張劑

第6章全球支氣管擴張劑市場，依給藥途徑，2019-2031

  • 口服
  • 鼻腔（吸入）
  • 注射

第 7 章 全球支氣管擴張劑市場，依適應症分類，2019-2031 年

  • 氣喘
  • 慢性阻塞性肺病（COPD）
  • 其他（慢性支氣管炎等）

第8章全球支氣管擴張劑市場，依通路，2019-2031

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第9章全球支氣管擴張劑市場，按地區，2019-2031

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第10章競爭格局

  • 公司簡介
    • GSK plc.
    • Mylan NV
    • Mylan NV
    • Merck &Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva

第11章 章節

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI6679

The global bronchodilators market was valued US$ 22.85 Bn in 2023 and is expected to reach US$ 30.44 Bn by 2031, growing at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 22.85 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 3.60% 2030/2031 Value Projection: US$ 30.44 Bn
Figure 1. Global Bronchodilators Market Share (%), By Region, 2023
Global Bronchodilators Market - IMG1

Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.

Market Dynamics:

The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.

Key features of the study:

  • This report provides in-depth analysis of the global bronchodilators market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market

Detailed Segmentation:

  • Global Bronchodilators Market, By Drug Class
    • Beta-adrenergic Bronchodilators
    • Xanthine Derivatives
    • Anticholinergic Bronchodilators
  • Global Bronchodilators Market, By Route of Administration
    • Oral
    • Nasal (inhalable)
    • Injectable
  • Global Bronchodilators Market, By Indication
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Others (Chronic bronchitis, etc.)
  • Global Bronchodilators Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Bronchodilators Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Top Companies in the Global Bronchodilators Market:
    • GSK plc.
    • AbbVie Inc.
    • AstraZeneca
    • Mylan N.V.
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Product Approval
    • Stringent Regulatory Environment
    • Increasing Awareness Campaigns
  • Key Highlights
  • Regulatory Scenario
  • Market Trends
  • Pipeline Analysis
  • Product Launch/Approval
  • PEST Analysis
  • PORTER's Analysis
  • Epidemiology
  • Treatment Algorithm (Patient Journey)
  • Treatment Option Analysis
  • New Investments by Major Market Players
  • Pricing Analysis
  • Disease Awareness Programs
  • Treatment Safety and Efficacy Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Bronchodilators Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Bronchodilators Market, By Drug Class, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Beta-adrenergic Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Xanthine Derivatives
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Anticholinergic Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

6. Global Bronchodilators Market, By Route of Administration, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Nasal (inhalable)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

7. Global Bronchodilators Market, By Indication, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Asthma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Others (Chronic bronchitis, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

8. Global Bronchodilators Market, By Distribution Channel, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 201s9-2031, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

9. Global Bronchodilators Market, By Region, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Country, 2020 -2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profile
    • GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mylan N.V.
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us